언어 선택

LRRC32

LRRC32 분자 정보

영어 이름	Transforming growth factor beta activator LRRC32	시판 약물 수	0
임상 약물 수	7	표적 별명	Leucine Rich Repeat Containing 32，D11S833E，Garpin，Leucine-Rich Repeat-Containing Protein 32，LRRC32，Transforming Growth Factor Beta Activator LRRC32，GARP，Glycoprotein A Repetitions Predominant
최고 연구 개발 단계	Phase 3 Clinical

영어 이름	Transforming growth factor beta activator LRRC32
표적 별명	Leucine Rich Repeat Containing 32，D11S833E，Garpin，Leucine-Rich Repeat-Containing Protein 32，LRRC32，Transforming Growth Factor Beta Activator LRRC32，GARP，Glycoprotein A Repetitions Predominant
시판 약물 수	0
임상 약물 수	7
최고 연구 개발 단계	Phase 3 Clinical

LRRC32 제품 목록

속성
Protein (1)
제품 라이브러리
온라인 (1)
종
Human (1)
태그
Fc Tag (1)
마커
Unconjugated (1)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
LR2-H5256	Human	HEK293	Human LRRC32 / GARP / Garpin Protein, Fc Tag

총 수량1

LRRC32분자 배경

Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells. LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells. The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation.

LRRC32분자 별명

GARP,Garpin,D11S833E

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Livmoniplimab	MGH-8; AGRX-115; ABBV-151; MHG-8; ARGX-115	Phase 3 Clinical	Argenx Se	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours	상세
Anti-GARP Chimeric Antigen Receptor T Cell Therapy (Ohio State University Comprehensive Cancer Center)		Phase 1 Clinical	Ohio State University Comprehensive Cancer Center	Glioma	상세
PBA-0111	PBA-0111	Phase 1 Clinical	Pure Biologics SA	Sarcoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	상세
HLX-6018	HLX-6018; HLX6018	Phase 1 Clinical		Idiopathic Pulmonary Fibrosis	상세
JYB-1907	JYB-1907	Phase 1 Clinical	Jiangxi Jemincare Group Co Ltd	Solid tumours	상세
DS-1055	DS-1055; DS-1055a	Phase 1 Clinical	Daiichi Sankyo Co Ltd	Neoplasms; Solid tumours	상세
HLX-60	HLX-60	Phase 1 Clinical		Lymphoma; Solid tumours	상세